Physician profile
Adele Bulahan
NPI 1194265520
$1,015.75
in general payments reported to CMS, 2019-2025
20 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $308 · 2022: $429 · 2023: $105 · 2024: $61.87 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $279.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $143.28 | 2021-2023 | Gardasil 9, M-M-R II, Vaxelis |
| Novartis Pharmaceuticals Corporation | $134.87 | 2021-2023 | |
| Alkermes, INC. | $129.42 | 2022 | |
| Glaxosmithkline, LLC. | $101.61 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.09 | 2021-2022 | |
| Pfizer INC. | $65.64 | 2022-2025 | |
| Cranial Technologies, INC | $63.27 | 2021-2023 | Doc Band |
| Amgen INC. | $43.37 | 2024 | Tepezza |
| Horizon Therapeutics Plc | $37.61 | 2021-2022 | |
| Abbvie INC. | $27.12 | 2021 | |
| Exact Sciences Corporation | $26.97 | 2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $24.28 | 2025 | Zepbound, Mounjaro |
| Ultragenyx Pharmaceutical INC. | $23.46 | 2022 | |
| Xeris Pharmaceuticals, INC. | $23.08 | 2022 | |
| Hologic Sales and Service, LLC | $22.70 | 2025 | Aptima, Thinprep 2000 Processor |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $18.50 | 2024 | Immunocap |
| Sanofi Pasteur INC. | $18.11 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.45 | 2021 | |
| Sobi, INC | $15.31 | 2021 | |
| Cipher Pharmaceuticals US LLC | $14.61 | 2025 | Spinosad, Natroba |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adele Bulahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.